Updates are available Correction dated 2020-02-15
Click to view Correction: https://doi.org/10.1007/s10557-019-06929-2
-
Authors
Tate, Mitchel
Higgins, Gavin C.
De Blasio, Miles J.
Lindblom, Runa
Prakoso, Darnel
Deo, Minh
Kiriazis, Helen
Park, Min
Baeza-Garza, Carlos D.
Caldwell, Stuart T.
Hartley, Richard C.
Krieg, Thomas
Murphy, Michael P.
Coughlan, Melinda T.
Ritchie, Rebecca H. http://orcid.org/0000-0002-8610-0058
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (ID1059660)
Medical Research Council (MC_U105663142)
Wellcome Trust (110159/Z/15/Z)
Biotechnology and Biological Sciences Research Council (BB/I012826/1)
Wellcome Trust (110158/Z/15/Z)
- License Information
-
More Information
Article History
First Online: 25 October 2019
Change Date: 15 February 2020
Change Type: Correction
Change Date: 15 February 2020
Change Type: Correction
Change Details: The article “The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart”
Change Details: The article ���The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart���
Compliance with Ethical Standards
: All activities involving the use of animals for research were approved by the Alfred Medical Research Education Precinct (AMREP) Animal Ethics Committee and were conducted according to guidelines of the National Health and Medical Research Council of Australia for animal experimentation. For all experiments, we have included flow charts for the reporting of animal use and analysis in preclinical studies
: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. However, MPM and RCH declare that they are inventors on a patent that includes MitoGamide: Mitochondria-targeted dicarbonyl sequestering compounds. Murphy, M. P.; Smith, R.A. J.; Hartley, R. C. WO 2015075200. A1.
